2. Use a He2 secondary inhibitory antibody to make a drug to extend TTP of a disease or MBC in patients with metabolic breast cancer (div.sol). (No. 399-06).
The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.LA INVENCIÓN PROPORCIONA EL USO DE UN ANTICUERPO INHIBIDOR DE LA DIMERIZACIÓN DE HER2 PARA PREPARAR MEDICAMENTO PARA EXTENDER EL TIEMPO DE PROGRESION DE UNA ENFERMEDAD (TTP) O SUPERVIVENCIA EN UN PACIENTE CON CANCER DE MAMA METASTASICO (MBC)